Abstract Retinal ganglion cells (RGCs) are highly specialized neuronal cells located in the innermost layer of the retina and serve to relay visual information to the brain, with their axons collectively forming the optic nerve. Loss or damage to the RGCs results in visual impairment and ultimately blindness. Several diseases affect the RGCs exclusively, the most common being glaucoma. Even though the mechanisms of glaucoma are not fully understood, some common treatments can delay cell death. Pharmacological intervention or laser therapy is thought to reduce the intraocular pressure and therefore reduce cell damage, but ultimately these therapies are often transient and stop working. Additional strategies to rescue RGCs and prevent their loss are being explored. Human pluripotent stem cells (hPSCs), including both embryonic and induced pluripotent stem cells, serve as an effective in vitro model of retinal development and repair. In addition, RGCs differentiated from hPSCs can also provide an unlimited source of transplantable cells for use in cell replacement strategies. This review addresses some of the technical and clinical issues and concerns with generating bone fide RGCs in vitro. We also outline the potential applications of hPSC-derived RGCs as a useful tool in disease modeling and drug screening in order to advance knowledge of optic neuropathies.
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Serving to connect the eye with the brain, RGCs play a critical role in transmitting visual information in the central nervous system. As such, damage to or degeneration of these important cells often results in visual impairment and eventually blindness. While few treatment options exist to repair damaged or degenerating RGCs, efforts have often focused upon the restoration of existing RGCs through approaches to encourage enhanced survival of these cells as well as efforts to promote axonal regeneration [1, 2 • , 3, 4] . However, once a critical number of RGCs have been lost, it will likely be necessary to identify a suitable source of cells for replacement purposes, and design strategies to encourage proper survival and integration of cells replacement cells.
Human pluripotent stem cells (hPSCs), including both embryonic and induced pluripotent stem cells, have received considerable attention in recent years for their potential to serve as an effective in vitro model of retinal development and repair [5] [6] [7] 8 [11] [12] [13] [14] . Furthermore, RGCs differentiated from hPSCs have also been proposed as a powerful, unlimited source of cells for neuroprotective and cell replacement applications [15] [16] [17] . However, to date there exist no effective therapies for RGC damage or degeneration and in order for the potential of hPSCs to be realized for such applications, a number of obstacles exist which must be overcome. [18, 19] . While glaucoma is the most common of the optic neuropathies with a current incidence of greater than 60 million people worldwide [20, 21] , the optic neuropathies include a variety of other disorders including Leber's hereditary optic neuropathy (LHON) and ischemic optic neuropathies [22] [23] [24] . The end result of each of the optic neuropathies is the loss of RGCs, but the underlying causes are many and varied. As such, the development of therapeutic approaches for the treatment of optic neuropathies has also been varied. The preservation of existing RGCs is often viewed as the most promising approach for the development of treatments for optic neuropathies [22] [23] [24] , due to the fact that existing cells are at least partially integrated into the retinal circuitry. In many forms of glaucoma, an increase in intraocular pressure (IOP) is thought to serve as a trigger resulting in damage to RGCs, and eventually leading to the loss of these cells [25] [26] [27] . As such, a common existing treatment for glaucomatous neurodegeneration involves the reduction of IOP with interventions including eye drops and laser treatments being among the most common approaches [28] [29] [30] [31] . These approaches to lower IOP have been successful in delaying glaucomatous neurodegeneration and prolonging vision, but do not prevent the subsequent damage to, and loss of, RGCs. This eventual loss of RGCs is due to the fact that these interventions to lower IOP have just transient effects, while elevated IOP will persist beyond the treatment period. Furthermore, fluctuations in IOP levels are known to occur, particularly those diurnal in nature [32] [33] [34] . Thus, existing interventions may not effectively prevent subsequent damage to RGCs as IOP levels are known to fluctuate.
Due to the transient nature of interventions to lower IOP, additional strategies to rescue RGCs and prevent their eventual loss have been a popular topic of research for a number of years. To this end, pharmacological approaches have been particularly attractive for the development of neuroprotective strategies. In particular, neurotrophic factors have received considerable attention for their potential ability to delay or halt neurodegeneration. Within the optic neuropathies, neurotrophic factors including brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF) have been the subject of numerous studies due to their documented ability to prevent apoptosis and prolong the viability and functionality of RGCs [35] [36] [37] . While these neurotrophic factors have been successful in this capacity, this success has been transient in nature as these protective effects do not persist for prolonged periods of time and eventually, RGCs suffer damage and are lost. While the reasons for this transient nature of neurotrophic factors and their effects on RGCs are likely varied, research has demonstrated that RGCs tend to become acclimated to elevated levels of these neurotrophic factors and become desensitized to their effects, often through the downregulation of specific receptors [38] [39] [40] . Thus, further examination of factors that may aid in the neuroprotection of RGCs is warranted, with the goal of identifying those factors that may confer a long-lasting neuroprotective effect and successfully rescue the degenerative phenotype of optic neuropathies.
Stem Cells and Retinal Ganglion Cells
The ability to derive RGCs from stem cells offers numerous exciting opportunities for investigation, including the underlying mechanisms responsible for their damage and loss in optic neuropathies. Furthermore, stem cell-derived RGCs can also be developed as a tool for cell replacement following the degeneration and loss of endogenous RGCs. A variety of types of stem cells exist, each with specific properties and characteristics that enable their use for a variety of applications, both basic and translational in nature. In recent years, however, the ability to derive retinal neurons from pluripotent stem cells has received considerable attention and is the subject of ongoing investigation [ While many studies have demonstrated the ability to derive retinal cells from hPSCs, the demonstration of yielding RGCs from hPSCs has been less extensively studied. Most studies to date have focused on the differentiation of photoreceptors and retinal pigment epithelium from hPSCs [5-10, 12-14, 42, 52, 58-60], likely due in part to the number of prevalence of blinding disorders that adversely affect these cell types. Just as important, however, is the fact that photoreceptors and retinal pigment epithelium cells can be identified in vitro due to the existence of specific markers that can be utilized to identify these cell types. The definitive identification of RGCs, however, proves to be more difficult. While some markers can definitely identify RGCs within the retina itself, these markers are not truly specific to RGCs. When derived from hPSCs, the pluripotent nature of these cells requires careful consideration about the specificity of markers utilized to identify differentiated cell types. The definitive identification of RGCs from a pluripotent source necessitates that a number of criteria are met (Table 1) . First, differentiated hPSCs should express markers characteristic of RGCs, including commonly identified markers such as Brn3, Islet1, Pax6, etc. Additionally, these prospective RGCs should possess characteristic morphological features. In particular, RGCs are unique within the retina due to the extensive outgrowth and elongation of axonal projections, as well as the existence of a significant number of dendritic extensions [61] [62] [63] [64] . Similarly, presumptive hPSC-derived RGCs should possess the ability to develop comparable morphological characteristics. Furthermore, due to the fact that many of these features are shared with some other nonretinal neuronal populations of the central nervous system [65, 66] , care should be taken to demonstrate the retinal lineage of presumptive hPSC-derived RGCs, particularly through the stepwise, documented differentiation of RGCs through all of the major stages of retinogenesis. Finally, upon the acquisition of the above phenotypic characteristics of RGCs, the proper physiological activity of these cells would need to be documented [67, 68] . As RGCs in vivo are responsible for conducting neural information from the eye to the brain, the functionality of hPSC-derived RGCs requires their physiological activity.
Given the above criteria necessary for the identification of RGCs from a pluripotent source, it is not surprising that a general lack of studies exist focused upon this topic. However, the potential for hPSCs to yield RGC-like cells has received increased attention in recent years. While not necessarily focused upon the specific differentiation of RGCs, a number of groups have documented the expression of some RGC-associated markers in the process of differentiating retinal cells from hPSCs ( As efforts progress in the coming years, it is likely that the ability to derive RGCs from hPSCs will become standardized and more routine. Once this occurs, the potential will exist for the translational application of these differentiated cells. The ability to utilize patient-derived hiPSCs as an in vitro model of human disease will likely be among the first applications to realize this potential. When hiPSCs are generated from specific patient samples, particularly those with a genetic basis underlying a disease phenotype, the successful differentiation of the affected cell type can serve as an effective model of disease progression [72, 73] . Such an ability has been demonstrated in a variety of other systems, including other cell types of the retina including photoreceptors and retinal pigment epithelium [9, 16, 51] , although similar efforts to model optic neuropathies in vitro have been limited to date. Recently, Tucker et al. [48 • ] examined the role of autophagy in RGC-like cells derived from hiPSCs that were generated from a patient with a form of normal tension glaucoma, with the demonstration that patient hiPSC-derived RGCs exhibited differences in LC3 expression associated with autophagy deficits. Similarly, Minegishi et al. [74] demonstrated the ability to derive hiPSCs from a patient with a related form of normal tension glaucoma. Although the differentiation of these hiPSCs to an RGC fate was not demonstrated, these cells did demonstrate various features associated with the progression of normal tension glaucoma. Thus, while tremendous potential remains for hiPSCs to serve as an effective model of disease progression, preliminary studies demonstrate the feasibility of such an approach. Along with the potential for hiPSC-derived RGCs to act as an in vitro disese model, they can also serve as a unique tool for drug development purposes [75] [76] [77] . Due to the ability to obtain unlimited numbers of hiPSCs, along with the ability to direct the differentiation of these cells to a retinal lineage (including RGCs), the potential exists to test the efficacy of novel compounds upon diseased cell types for their therapeutic potential. Such an ability to utilize hiPSCs for drug screening purposes has been preliminarily demonstrated in a variety of other system to date, including within the retina [9, 16, 51] . In order for this potential to be realized for RGCs, a clearly identifiable and measurable disease-related phenotype must exist by which to test the efficacy of such compounds. Given this ability, the potential for high-throughput screening approaches exists as well, potentially expediting or enabling the development of new drugs for optic neuropathies.
Beyond the applications of hiPSC-derived RGCs in vitro, the potential exists for the development of cellular replacement approaches, particularly following the loss of RGCs in response to optic neuropathies or other related injuries. Cellular replacement with hPSCs is an attractive option for future therapeutic approaches to optic neuropathies, particularly at later stages of the disease process. While pharmacological intervention may be effective at early stages of disease progression, cellular replacement becomes the only viable option once significant cell loss has occurred. The potential for cellular replacement with hPSCs has been demonstrated in preliminary studies typically in rodent models, particularly including cells of the outer layers of the retina such as retinal pigment epithelium and photoreceptors [5-7, 14, 52] . The successful replacement of RGCs, however, will likely be more difficult due to certain characteristics of RGCs, particularly their need to extend axons across long distances. True replacement of
RGCs will need to demonstrate that a number of criteria are met. First, transplanted cells will need to integrate into the appropriate location in the retina, namely the retinal ganglion cell layer. Following successful integration, these cells will need to extend axons into the nerve fiber layer, enter the optic nerve and extend further into the visual areas of the brain. This axonal elongation also requires the proper ipsilateral or contralateral projection into the brain, particularly in humans and other primates [78, 79] . If these requirements are met, axons must match with appropriate post-synaptic targets and establish functional connections, and axons need to be myelinated to properly convey neural impulses. Beyond all of the requirements for axonal elongation and synaptogenesis, similar processes must also occur in RGC dendrites to receive synaptic input and functionally integrate into the retinal network. Finally, transplanted cells would need to be capable of surviving the local microenvironment, which is often highly toxic to RGCs and resulted in the original loss of host cells in the first place [80] . Thus, while the potential exists for hPSC-derived RGCs to serve as a tool for cellular replacement approaches, their complex and unique nature within the retina also serves to complicate efforts to replace them once they have been lost due to disease-related processes.
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